KDR and kidney cancer: Without an OS benefit in the STRAC trial and with neither DFS nor OS in the other five phase 3 trials of adjuvant VEGFR TKIs, the US National Comprehensive Cancer Network (NCCN) kidney cancer guidelines label sunitinib a Category 3 recommendation and its adjuvant use has fallen out of favor in clinical practice [17].